FDA Seeks to Halt Crestor Ad

WASHINGTON, D.C. The Food and Drug Administration has asked AstraZeneca to “immediately cease the dissemination” of an ad touting the safety of its cholesterol drug Crestor, calling the claims misleading.

Client representative Emily Denney said the execution was intended only to run for a short time and the FDA has been advised that it is no longer being used.

Quantum in Parsippany, N.J., a unit of WPP Group’s CommonHealth, has been lead agency for Crestor, which competes with such brands as Pfizer’s Lipitor and Merck’s Zocor.

“The ‘Patient Safety’ print execution makes false or misleading safety claims that minimize the risks associated with Crestor, thereby suggesting that Crestor is safer than has been demonstrated by substantial evidence or substantial clinical experience,” the FDA said in a letter dated Tuesday.

The ad in question appeared in The Washington Post on Nov. 23, prompting Dr. Sidney Wolfe of the consumer group Public Citizen to complain to the FDA. Wolfe has sought to have Crestor withdrawn because of its rate of liver problems.

Crestor is one of a group of medications called statins that are used to lower cholesterol. Crestor’s prescribing information includes warnings about side effects including possible liver damage or failure.

In its complaint the FDA took issue with claims that FDA scientists have confirmed that concerns about the safety of the drug have no basis.

The agency has published no statement on its Web site saying the concerns about Crestor have no basis, the FDA said.

In addition, the agency said, “recent public statements made by the agency contradict that conclusion.”

The FDA letter noted a recent statement by Dr. Steven Galson, its acting director for drug evaluation and research, that the agency “has been very concerned about Crestor since the day it was approved, and we’ve been watching it very carefully.”

On Wednesday, AstraZeneca slid 81 cents, or 2.2 percent, to close at $35.88 on the New York Stock Exchange. The stock has traded in a 52-week range of $36.52 to $51.20.

Copyright 2004 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.